ClinicalTrials.gg
Status unknownNCT00025688Updated Jul 24, 2008

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

A Phase 3 interventional study of carboplatin and paclitaxel in Breast Cancer, sponsored by Theradex. Status unknown at 25 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-07-24.

Sponsored by Theradex · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2006), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 145 studies testing carboplatin in Breast Neoplasms — 17 open to participants now, 34 under way, 9 of them phase 3. Carboplatin · Breast Neoplasms.

Started
2001
with 1 other
Phase 3
17 of 145
3 open now
Registered
11th of 145
by date

Among the 145 studies testing carboplatin in Breast Neoplasms, this one is one of 2 that started in 2001, is one of 17 in phase 3, and was the 11th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 145 studies testing carboplatin in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing carboplatin in Breast Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.

Read the detailed description

OBJECTIVES:

  • Compare the objective response rate in women treated with paclitaxel with or without carboplatin as first-line chemotherapy for metastatic breast cancer.
  • Compare the overall survival, time to disease progression, and duration of response in these patients treated with these regimens.
  • Compare the safety of these regimens in this patient population.
  • Compare the quality of life of these patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior adjuvant chemotherapy (yes vs no) and ECOG performance status (0-1 vs 2). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive paclitaxel IV over 1 hour weekly for 3 weeks.
  • Arm II:Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes weekly for 3 weeks.

Treatment in both arms continues every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, before each course during study, and then after completion of study.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 220 patients will be accrued for this study.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • stage IV breast cancer
  • recurrent breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • or cytologically confirmed breast cancer

    • Must have clinical evidence of stage IV (M1) disease
  • /neu negative (0, 1+, or 2+ by immunohistochemistry or fluorescent in situ hybridization) OR status unknown
  • At least 1

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
    • Patients with bone-only disease are not eligible
  • Ineligible if currently experiencing a complete or partial response to prior hormonal therapy
  • Patients with disease progression after prior response to hormonal therapy are eligible
  • Disease progression without prior hormonal therapy is allowed
  • Stable or asymptomatic allowed if:

    • Other measurable disease exists
    • Cranial irradiation completed and brain metastasis stable for at least 4 weeks before study
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Sex:

  • Female

Menopausal status:

  • Pre- or

Performance status:

  • 0-2

:

  • At least 3 months

Hematopoietic:

  • at least 1,500/mm\^3
  • count at least 100,000/mm\^3

Hepatic:

  • no greater than 1.5 times (ULN)
  • and ALT no greater than 2 times ULN

Renal:

  • Creatinine no greater than 2 times ULN
  • Corrected calcium less than 12 mg/dL

Cardiovascular:

  • No class III or IV heart disease
  • No documented myocardial infarction within the past 6 months
  • No congestive heart failure
  • No unstable angina
  • No pericardial effusion or arrhythmia

Other:

  • No active serious infection
  • No prior significant allergic reactions to drugs containing Cremophor, such as teniposide, cyclosporine, or vitamin K
  • No clinically significant (greater than grade 1) peripheral neuropathy
  • No other serious underlying medical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • More than 6 months since prior adjuvant bone marrow or peripheral blood stem cell transplantation
  • More than 6 months since prior monoclonal antibody therapy
  • More than 6 months since prior adjuvant vaccine therapy
  • No prior trastuzumab (Herceptin)
  • No concurrent anticancer immunotherapy

Chemotherapy:

  • No prior chemotherapy for breast cancer
  • More than 6 months since prior adjuvant high-dose chemotherapy
  • More than 6 months since prior adjuvant taxanes or any other adjuvant chemotherapy
  • Prior adjuvant taxanes allowed only if administered every 3 weeks

Endocrine therapy:

  • See Disease Characteristics
  • Any number of prior hormonal therapies for metastatic breast cancer allowed

    • Patients with definite signs of progression may begin study therapy immediately after stopping hormonal therapy
  • No concurrent anticancer hormonal agents (including megestrol)

Radiotherapy:

  • At least 3 weeks since prior radiotherapy (4 weeks for cranial irradiation)
  • No prior radiotherapy to 30% or more of bone marrow
  • No concurrent radiotherapy except for palliation of painful bone metastasis or pathologic fractures to the area of known lytic disease

Surgery:

  • At least 3 weeks since prior major surgery

Other:

  • More than 6 months since prior neoadjuvant therapy
  • No other concurrent anticancer drugs
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized

Interventions

06

Study locations

25 sites
  • Highlands Oncology Group
    Springdale, Arkansas 72764, United States
  • Monterey Bay Oncology
    Monterey, California 93940, United States
  • Wilshire Oncology Medical Group, Inc.
    Pomona, California 91767-3021, United States
  • University of California Davis Cancer Center
    Sacramento, California 95817, United States
  • New Britain General Hospital
    New Britain, Connecticut 06050, United States
  • Center for Hematology and Oncology
    Boca Raton, Florida 33486, United States
  • Cancer Research Network, Inc.
    Hollywood, Florida 33020, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • MacNeal Cancer Center
    Berwyn, Illinois 60402, United States
  • Oncology Specialists, SC
    Park Ridge, Illinois 60068, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Scarborough, Maine 04074, United States
  • Maryland Hematology/Oncology Associates
    Baltimore, Maryland 21236, United States
  • St. John's Mercy Medical Center
    Saint Louis, Missouri 63141, United States
  • St. Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Finger Lakes Community Cancer Center
    Clifton Springs, New York 14432, United States
  • Clinical Hematology & Oncology Service, Inc.
    Akron, Ohio 44302, United States
  • Scranton Hematology-Oncology
    Scranton, Pennsylvania 18510, United States
  • East Tennessee Oncology/Hematology, P.C.
    Knoxville, Tennessee 37920, United States
  • West Clinic
    Memphis, Tennessee 38120, United States
  • Texas Cancer Care
    Fort Worth, Texas 76104, United States
  • Oncology Consultants
    Houston, Texas 77024, United States
  • Scott and White Clinic
    Temple, Texas 76508, United States
  • Northern Virginia Oncology Group, P.C.
    Fairfax, Virginia 22031, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Dean Medical Center
    Madison, Wisconsin 53715, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00025688
Lead sponsor
Theradex
First posted
Aug 5, 2003
Start date
Jan 2001
Last update
Jul 24, 2008

Study contacts

Edith A. Perez, MD
study chair · Mayo Clinic
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Paclitaxel

Start the discussion